Elligint Health, a New Jersey company that sells care management and utilization management software to US health insurers, has acquired Laguna Health, an Israeli startup whose conversational AI supports the care managers who phone health-plan members. The deal was announced on November 12, 2026.
The companies did not disclose the price. Israeli business site CTech reported that the deal was estimated at tens of millions of dollars, without giving a source for the figure.
Laguna becomes a wholly owned subsidiary of Elligint and keeps its name, products and website. Co-founder Yoni Shtein stays on as chief executive, and customers of both companies keep the teams they already work with. CTech reported that Laguna's Tel Aviv office will become Elligint's AI development arm and that the Israeli headcount is set to double.
What Laguna built
Laguna sells three products to health plans. Laguna Companion acts as an assistant for care managers: it prepares them before an outreach call, offers clinical prompts while the conversation is going on, and writes the documentation once the call ends. Laguna Insight reviews every member call against the plan's own clinical and operational standards, replacing the usual practice of having supervisors spot-check a small sample. Insight was named one of TIME's Best Inventions of 2024, according to the announcement.
The third product, LISA, is an agentic AI assistant that contacts members on its own, runs standard health assessments and hands members over to a human care manager when needed.
Laguna says its documentation reaches 99% accuracy on clinical content and points to a peer-reviewed randomized controlled trial published in the Journal of Healthcare Management. An unnamed multi-state health plan cut the time its care managers spent on documentation by 66%, according to a customer case study cited in the release. These figures come from the companies and were not independently checked.
CTech noted that Laguna began with a narrower focus: helping patients recover after leaving hospital, using digital tools, data and behavioural health support to lower the chance of readmission.
“Elligint shares our belief that AI should support care managers, not replace them.”
Why Elligint is buying
Elligint's main product is Helios, a platform health plans use to run care management and utilization management. The company says it manages more than 13 million lives across all 50 US states. Chris Caramanico is its chief executive.
Caramanico said health plans want AI that helps care teams in their everyday work and want evidence that it is accurate and safe, and that Laguna already has that evidence from its work with health plans. He described Laguna as a low-risk use of AI that runs inside the systems plans already use, and said the two companies together could bring AI into care management faster than either could alone.
Shtein said customers chose Laguna because it gives care managers more time with members and gives managers a view of every conversation. He said Elligint's reach across health plans would let Laguna reach many more care teams.
What happens to customers
Health plans can keep using Laguna's products on their own, inside whatever care management system they run, with no integration work needed to go live. Plans can also deploy Laguna alongside Helios.
Elligint plans to connect Laguna's AI more closely with Helios over the coming quarters, starting with Laguna Companion. Each Laguna product will still be sold separately, including to plans that use rival core systems, HIT Consultant reported.
The founders and the funding
Laguna was founded in 2020 by Shtein and Yael Peled Adam and has offices in Edison, New Jersey, and Tel Aviv. According to CTech, Shtein helped set up the insurance business at RPX Corp. and later invested at Fortress Investment Group. Peled Adam co-founded the digital health startup Vim, was chief product officer at e-commerce company Bond and held senior roles at Microsoft and Amazon.
The startup raised about $30 million in total, CTech reported. That included a $6.6 million seed round announced in 2021, co-led by Pitango HealthTech and LionBird, and a $15 million Series A in May 2023, co-led by SemperVirens and HC9 Ventures. Arkin and private investors also took part, according to CTech, and the press release also lists A-Squared Ventures among Laguna's institutional backers.
CTech put Laguna's staff at about 20 people in Tel Aviv. Elligint plans to add software developers, AI engineers and sales staff focused on the US market there.




